159 related articles for article (PubMed ID: 37922877)
1. Epitope base editing: Non-malignant stem cells are going undercover.
Saniei S; Wagenblast E
Cell Stem Cell; 2023 Nov; 30(11):1400-1402. PubMed ID: 37922877
[TBL] [Abstract][Full Text] [Related]
2. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia.
Casirati G; Cosentino A; Mucci A; Salah Mahmoud M; Ugarte Zabala I; Zeng J; Ficarro SB; Klatt D; Brendel C; Rambaldi A; Ritz J; Marto JA; Pellin D; Bauer DE; Armstrong SA; Genovese P
Nature; 2023 Sep; 621(7978):404-414. PubMed ID: 37648862
[TBL] [Abstract][Full Text] [Related]
3. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
4. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
[TBL] [Abstract][Full Text] [Related]
5. Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy.
Marone R; Landmann E; Devaux A; Lepore R; Seyres D; Zuin J; Burgold T; Engdahl C; Capoferri G; Dell'Aglio A; Larrue C; Simonetta F; Rositzka J; Rhiel M; Andrieux G; Gallagher DN; Schröder MS; Wiederkehr A; Sinopoli A; Do Sacramento V; Haydn A; Garcia-Prat L; Divsalar C; Camus A; Xu L; Bordoli L; Schwede T; Porteus M; Tamburini J; Corn JE; Cathomen T; Cornu TI; Urlinger S; Jeker LT
J Exp Med; 2023 Dec; 220(12):. PubMed ID: 37773046
[TBL] [Abstract][Full Text] [Related]
6. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T cells for acute myeloid leukemia.
Fetsch V; Zeiser R
Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
[TBL] [Abstract][Full Text] [Related]
8. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
Lee JB; Chen B; Vasic D; Law AD; Zhang L
Blood Rev; 2019 May; 35():18-31. PubMed ID: 30826141
[TBL] [Abstract][Full Text] [Related]
11. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
[TBL] [Abstract][Full Text] [Related]
12. CD70 CAR T cells in AML: Form follows function.
Mirazee J; Shah NN
Cell Rep Med; 2022 May; 3(5):100639. PubMed ID: 35584621
[TBL] [Abstract][Full Text] [Related]
13. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
[TBL] [Abstract][Full Text] [Related]
15. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
16. Stem cells in disguise.
Casirati G
Science; 2024 Feb; 383(6684):714. PubMed ID: 38359127
[TBL] [Abstract][Full Text] [Related]
17. [IL-1RAP as a candidate for CAR T-cells immunotherapy].
Neto Da Rocha M; Trad R; Warda W; Haderbache R; Bouquet L; Nicod C; Deschamps M; Ferrand C
Med Sci (Paris); 2019; 35(6-7):497-500. PubMed ID: 31274074
[No Abstract] [Full Text] [Related]
18. Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.
Prommersberger S; Jetani H; Danhof S; Monjezi R; Nerreter T; Beckmann J; Einsele H; Hudecek M
Curr Res Transl Med; 2018 May; 66(2):37-38. PubMed ID: 29655962
[No Abstract] [Full Text] [Related]
19. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
Gu B; Chu J; Wu D
Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]